Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Results Conference Call March 27, 2024 8:30 AM ET Company Participants Scott Harris - CMO Vipin Garg - CEO Rich Eisenstadt - CFO Scot Roberts - CSO Conference Call Participants Corinne Jenkins - Goldman Sachs Jonathan Wolleben - JMP Liisa Bayko - Evercore Mayank Mamtani - B. Riley Patrick Trucchio - H.C. Wainwright Roger Song - Jefferies Seamus Fernandez - Guggenheim Yasmeen Rahimi - Piper Sandler Operator Good day, ladies and gentlemen, and welcome to the Altimmune Inc. ...

Exhibit 99.1 Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in a non-steat ...

公司业绩 - Altimmune公司将于2024年3月27日公布2023年第四季度和全年财务业绩，并提供业务更新[1] - Altimmune管理团队将于3月27日上午8:30举行电话会议，讨论财务业绩并提供业务更新[2] 公司产品 - Altimmune是一家专注于开发创新下一代治疗方案的临床阶段生物制药公司，主要产品候选药物pemvidutide正在开发用于治疗肥胖和代谢功能障碍相关脂肪肝病（MASH）[4]

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at htt ...

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company’s stock surged by more than 580% from its lowest level in 2023. This surge has brought its total market cap to over $608 million. Short squeeze continues Copy link to section ALT stock price has jumped sharply in the past few months in a high-volume environment. The most recent data shows that the three-month volume rose to $12.6 million. This we ...

Altimmune股价上涨原因 - 丹麦制药公司Zealand Pharma的临床试验更新是导致ALT股价上涨的原因[2] - Zealand Pharma的MASH肝病临床试验中发现6mg剂量的药物是安全的[3] 重量减轻市场趋势 - 重量减轻市场目前正蓬勃发展，多家公司竞相推出治疗肥胖的新药[4]

生物技术股票机会 - 生物技术股票可能是今年最具爆发力的机会之一[1] 制药公司收购 - 大型制药公司需要解决专利到期问题，可能会寻找具有创新药物的公司进行收购[2] 值得关注的生物技术公司 - Altimmune (ALT)是一个值得关注的生物技术公司[4] - Pyxis Oncology (PYXS)是一个值得关注的生物技术公司[7]

Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ:ALT). The acclaimed short seller has just released a damning short report on the company, saying that its only viable product, a weight-loss drug, has little chance of commercial success and will “bomb” in upcoming Phase 3 trials. As of this writing, ALT stock is down roughly 20%. Altimmune has been struggling for months, failing to demonstrate any real growth. Positive clinical trial results ...

抗肥胖药物市场 - 美国存在严重的肥胖问题，新的抗肥胖药物将为公司带来大量收入和利润[1] - 投资那些估值较低、专注于改进或开发优越减肥治疗方法的公司更为明智[1] - Altimmune (ALT) 的 GLP 1 药物 pemvidutide 在二期研究中表现出色，降低了参与者的体重[8] - ALT的市值远低于其实际价值，公司有可能成为收购目标[9] 药物研发与治疗 - Biohaven Therapeutics (BHVN) 正在开发一种药物，通过阻断肌肉抑制蛋白来减少脂肪并增加肌肉[4] - BHVN的药物 Taldefgrobep alfa 正在进行第三阶段测试，用于治疗一种罕见疾病脊髓肌萎缩症[4] - BHVN的药物 Taldefgrobep alfa 有望在中期获批作为脊髓肌萎缩症的治疗药物，并被医生“越权”开处方用于肥胖治疗[5] - Amgen (AMGN) 的两种抗肥胖药物 AMG 133 和 AMG 786 受到加拿大银行 BMO Capital 的看好，预计公司将在今年晚些时候发布有利数据[10] - AMG 786 是一种口服药物，具有重要优势，与大多数需要注射的 GLP 1 药物不同[11] - AMG-133 可能只需每月服用一次，而市场上的竞争对手需要每天或每周服用[12]

Key Points o + Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related obesity disorders, including Bardet-Biedl Syndrome (BBS) and hyperphagia, an extreme, uncontrollable and compulsive compulsion to eat. Rhythm is a Phase 3 clinical trial for hypothalamic disorder (HO), a type of obesity caused by a damaged h ...